KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Profit After Tax: 2012-2025

Historic Profit After Tax for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$447.5 million.

  • Sarepta Therapeutics' Profit After Tax fell 7027.37% to -$447.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.4 million, marking a year-over-year decrease of 625.17%. This contributed to the annual value of $235.2 million for FY2024, which is 143.89% up from last year.
  • Sarepta Therapeutics' Profit After Tax amounted to -$447.5 million in Q2 2025, which was down 381.36% from $159.0 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' Profit After Tax peaked at $159.0 million during Q4 2024, and registered a low of -$516.8 million during Q1 2023.
  • For the 3-year period, Sarepta Therapeutics' Profit After Tax averaged around -$83.1 million, with its median value being $6.5 million (2024).
  • Per our database at Business Quant, Sarepta Therapeutics' Profit After Tax soared by 248.37% in 2024 and then slumped by 7,027.37% in 2025.
  • Sarepta Therapeutics' Profit After Tax (Quarterly) stood at -$122.0 million in 2021, then rose by 10.44% to -$109.2 million in 2022, then soared by 141.79% to $45.7 million in 2023, then spiked by 248.37% to $159.0 million in 2024, then tumbled by 7,027.37% to -$447.5 million in 2025.
  • Its last three reported values are -$447.5 million in Q2 2025, $159.0 million for Q4 2024, and $33.6 million during Q3 2024.